Showing posts with label Leukemia. Show all posts
Showing posts with label Leukemia. Show all posts

What's New in Acute Leukemia Research and Treatment?

Researchers are now studying the causes, diagnosis, supportive care, and treatment of leukemia at many medical centers, university hospitals, and other institutions.
Genetics of leukemia
Scientists are making great progress in understanding how changes in a person's DNA can cause normal bone marrow cells to develop into leukemia cells. A greater understanding of the genes (regions of the DNA) involved in certain translocations that often occur in acute lymphocytic leukemia (ALL) is providing insight into why these cells become abnormal. Doctors are now looking to learn how to use these changes to help them determine a person's outlook and whether they should receive more or less intensive treatment.
As this information unfolds, it may also be used in developing newer targeted therapies against ALL. Drugs such as imatinib (Gleevec) and dasatinib (Sprycel) are examples of such treatments. They are now used in treating ALL patients who have the Philadelphia chromosome.
Gene expression profiling
This new lab technique is being studied to help identify and classify different cancers. Instead of looking at single genes, this test uses a special technology to look at the patterns of many different genes in the cancer cells at the same time. This may add to the information that comes from the current lab tests.
Detecting minimal residual disease
Progress in understanding DNA changes in ALL has already provided a highly sensitive test for detecting minimal residual disease after treatment -- when so few leukemia cells are present that they cannot be found by routine bone marrow tests.
The polymerase chain reaction (PCR) test can identify ALL cells based on their gene translocations or rearrangements. This test can find one leukemia cell among a million normal cells. A PCR test can be useful in determining how completely the chemotherapy has destroyed the ALL cells.
Doctors are now trying to determine what effect minimal residual disease has on a patient's outlook, and how this might affect the need for further or more intensive treatment.
Improving chemotherapy
Studies are in progress to find the most effective combination of chemotherapy drugs while limiting unwanted side effects. This is especially important in older patients, who often have a harder time tolerating current treatments.
New chemotherapy drugs are also being developed and tested. For example, clofarabine (Clolar) and nelarabine (Arranon) are drugs already approved to treat certain types of leukemias. Many other new drugs are also being studied.
Studies are also under way to determine whether patients with certain unfavorable prognostic features benefit from more intensive chemotherapy, and whether some ALL patients with favorable prognostic factors might not need as much treatment.
The effectiveness of chemotherapy may be limited in some cases because the leukemia cells become resistant to it. Researchers are now looking at ways to prevent or reverse this resistance by using other drugs along with chemotherapy.
Stem cell transplants
Researchers continue to refine stem cell transplants to try to increase their effectiveness, reduce complications and determine which patients are likely to be helped by this treatment. Many studies are under way to try to help determine exactly when allogeneic, autologous, and mini-transplants might best be used.
In people who have already received an allogeneic transplant and who relapse, doctors are studying donor leukocyte infusion. In this technique, the patient gets an infusion of white blood cells (leukocytes) from the same donor who contributed to stem cells for the original transplant. The hope is that the cells will boost the new immune system and add to the graft-versus-leukemia effect. Early study results have been promising, but more research of this approach is needed.
Monoclonal antibodies
These are man-made versions of immune system proteins (antibodies). They can be targeted to attach only to certain molecules, such as proteins on the surface of lymphocytes. Some monoclonal antibodies, such as rituximab (Rituxan) and alemtuzumab (Campath), are already used to treat some blood disorders and are now being studied for use against ALL. Early results have been favorable, but it is still too early to know for sure. Studies of several other monoclonal antibodies to treat ALL are now under way as well.

What if the Leukemia Doesn't Respond or Comes Back After Treatment?

If the leukemia is refractory -- that is, if it doesn't go away with the first treatment (which happens in about 10% to 20% of cases) -- then newer or more intensive doses of drugs may be tried, although they are less likely to work. A stem cell transplant may be tried if the leukemia can be put into at least partial remission. Clinical trials of new treatment approaches may also be considered.
If leukemia comes back (recurs) after initial treatment, it will most often do so in the bone marrow and blood. Occasionally, the brain or spinal fluid will be the first place it recurs.
In these cases, it is sometimes possible to put the leukemia into remission again with more chemotherapy, although this remission is not likely to last. For ALL patients with the Philadelphia chromosome, switching to or adding a newer targeted drug such as dasatinib (Sprycel) may be helpful. If a second remission can be achieved, most doctors will advise some type of stem cell transplant if possible.
If the leukemia doesn't go away or keeps coming back, eventually chemotherapy treatment will not be very helpful. If a stem cell transplant is not an option, a patient may want to consider taking part in a clinical trial of newer treatments.
Those who want to continue treatment to fight the leukemia as long as they can need to weigh the possible limited benefit of a new treatment against the possible downsides, including continued doctor visits and treatment side effects. Everyone has his or her own way of looking at this. In many cases, the doctor can estimate the response rate for the treatment being considered. Some people are tempted to try more chemotherapy, for example, even when their doctors say that the odds of benefit are less than 1%. In this situation, it is important to think about and understand your reasons for choosing this plan.
Palliative treatment
If a clinical trial is not an option, it is important at this time to focus on relieving the symptoms of the leukemia. This is known as palliative treatment. For example, the doctor may advise less intensive chemotherapy to try to slow the leukemia growth instead of trying to cure it.
As the leukemia grows in the bone marrow it may cause pain. It is important that you be as comfortable as possible. Treatments that may be helpful include radiation and appropriate pain-relieving medicines. If medicines such as aspirin and ibuprofen don't help with the pain, stronger opioid medicines such as morphine are likely to be helpful.
Other common symptoms from leukemia are low blood counts and fatigue. Medicines or blood transfusions may be needed to help correct these problems. Nausea and loss of appetite can be treated with medicines and high-calorie food supplements. Infections that occur may be treated with antibiotics.
At some point, you may benefit from hospice care. Most of the time, this can be given at home. The leukemia may be causing symptoms or problems that need attention, and hospice focuses on your comfort. Receiving hospice care doesn't mean you can't have treatment for the problems caused by the cancer or other health conditions. It just means that the focus of care is on living life as fully as possible and feeling as well as one can at this difficult stage.
Remember also that maintaining hope is important. The hope for a cure may not be as bright, but there is still hope for good times with family and friends -- times that can bring happiness and meaning. In a way, pausing at this time in your cancer treatment is an opportunity to refocus on the most important things in your life. This is the time to do some things you've always wanted to do and to stop doing the things you no longer want to do.

Typical Treatment of Acute Lymphocytic Leukemia

The main treatment for ALL in adults involves the long-term use of chemotherapy. In the last several years, doctors have begun to use more intensive chemotherapy regimens, which has led to more responses to treatment. But these regimens are also more likely to cause side effects, such as low white blood cell counts. Patients may need to take other drugs to help prevent or treat these side effects.
Treatment typically takes place in 3 phases:
  • remission induction
  • consolidation (intensification)
  • maintenance
The total treatment usually takes about 2 years, with the maintenance phase taking up most of this time. Treatment may be more or less intense, depending on the subtype of ALL and other prognostic factors.
An important part of treatment of ALL is central nervous system (CNS) prophylaxis -- treatment that is meant to ensure the leukemia does not spread to (or remain in) the brain or spinal cord. This is described in more detail below.
Remission induction
The initial phase of chemotherapy usually lasts for a month or so. Different combinations may be used, but they typically include the following drugs:
  • vincristine
  • dexamethasone or prednisone
  • doxorubicin (Adriamycin) or daunorubicin
Based on the patient's prognostic factors, some regimens may also include cyclophosphamide, L-asparaginase, etoposide, and/or high doses of methotrexate or cytarabine (ara-C) as part of the induction phase. For ALL patients who have the Philadelphia chromosome, targeted drugs such as imatinib (Gleevec) are often included as well.
Treatment to keep the leukemia cells from spreading to the CNS is often started at this time. This may include one or more of the following:
  • intrathecal chemotherapy (injected directly into the spinal fluid) with methotrexate, and sometimes with cytarabine or a steroid such as prednisone
  • high-dose IV methotrexate
  • radiation therapy to the brain
Induction chemotherapy can often have serious side effects, including life-threatening infections. For this reason, close monitoring and supportive care with other drugs such as antibiotics is important.
Consolidation (intensification)
If the patient goes into remission, the next phase often consists of fairly short course of chemotherapy, using many of the same drugs that were used for induction therapy. This typically lasts for a few months. Usually the drugs are given in high doses so that the treatment is still fairly intense. CNS prophylaxis may be continued at this time.
Some patients who go into remission are still at high risk for relapse, such as those who have certain subtypes of ALL or other poor prognostic factors. Doctors may suggest an allogeneic stem cell transplant (SCT) at this time, especially for those who have a brother or sister who would be a good donor match. An autologous SCT may be another option. The possible risks and benefits of stem cell transplants need to be weighed carefully, as it's still not clear how helpful they are. Patients considering this procedure may best be served by having it done in the context of a clinical trial at a center that has done a lot of SCT procedures.
Maintenance
After consolidation, the patient is generally put on a maintenance chemotherapy program of methotrexate and 6-mercaptopurine (6-MP). In some cases, this may be combined with other drugs such as vincristine and prednisone. For ALL patients who have the Philadelphia chromosome, targeted drugs such as imatinib (Gleevec) are often included as well. Maintenance usually lasts for about 2 years. CNS prophylaxis may be continued at this time.
Some doctors feel that maintenance therapy may not be needed for some leukemias such as T-cell ALL and mature B-cell ALL (Burkitt leukemia).
Response rates to treatment
In general, about 80% to 90% of adults will have complete remissions after these treatments. That means leukemia cells can no longer be seen in their bone marrow. Unfortunately, about half of these patients relapse, so the overall cure rate is around 30% to 40%. Again, these rates vary depending on the subtype of ALL and other prognostic factors. For example, long-term remission rates tend to be lower in older patients and those whose ALL cells contain the Philadelphia chromosome.

Complementary and Alternative Therapies

When you have cancer you are likely to hear about ways to treat your cancer or relieve symptoms that your doctor hasn't mentioned. Everyone from friends and family to Internet groups and Web sites offer ideas for what might help you. These methods can include vitamins, herbs, and special diets, or other methods such as acupuncture or massage, to name a few.
What exactly are complementary and alternative therapies?
Not everyone uses these terms the same way, and they are used to refer to many different methods, so it can be confusing. We use complementary to refer to treatments that are used along with your regular medical care. Alternative treatments are used instead of a doctor's medical treatment.
Complementary methods: Most complementary treatment methods are not offered as cures for cancer. Mainly, they are used to help you feel better. Some methods that are used along with regular treatment are meditation to reduce stress, acupuncture to help relieve pain, or peppermint tea to relieve nausea. Some complementary methods are known to help, while others have not been tested. Some have been proven not be helpful, and a few have even been found harmful.
Alternative treatments: Alternative treatments may be offered as cancer cures. These treatments have not been proven safe and effective in clinical trials. Some of these methods may pose danger, or have life-threatening side effects. But the biggest danger in most cases is that you may lose the chance to be helped by standard medical treatment. Delays or interruptions in your medical treatments may give the cancer more time to grow and make it less likely that treatment will help.
Finding out more
It is easy to see why people with cancer think about alternative methods. You want to do all you can to fight the cancer, and the idea of a treatment with no side effects sounds great. Sometimes medical treatments like chemotherapy can be hard to take, or they may no longer be working. But the truth is that most of these alternative methods have not been tested and proven to work in treating cancer.
As you consider your options, here are 3 important steps you can take:
  • Look for "red flags" that suggest fraud. Does the method promise to cure all or most cancers? Are you told not to have regular medical treatments? Is the treatment a "secret" that requires you to visit certain providers or travel to another country?
  • Talk to your doctor or nurse about any method you are thinking about using.
  • Contact us at 1-800-ACS-2345 to learn more about complementary and alternative methods in general and to find out about the specific methods you are looking at.
The choice is yours
Decisions about how to treat or manage your cancer are always yours to make. If you want to use a non-standard treatment, learn all you can about the method and talk to your doctor about it. With good information and the support of your health care team, you may be able to safely use the methods that can help you while avoiding those that could be harmful.

Clinical Trials

You may have had to make a lot of decisions since you've been told you have cancer. One of the most important decisions you will make is choosing which treatment is best for you. You may have heard about clinical trials being done for your type of cancer. Or maybe someone on your health care team has mentioned a clinical trial to you.
Clinical trials are carefully controlled research studies that are done with patients who volunteer for them. They are done to get a closer look at promising new treatments or procedures.
If you would like to take part in a clinical trial, you should start by asking your doctor if your clinic or hospital conducts clinical trials. You can also call our clinical trials matching service for a list of clinical trials that meet your medical needs. You can reach this service at 1-800-303-5691 or on our Web site at http://clinicaltrials.cancer.org. You can also get a list of current clinical trials by calling the National Cancer Institute's Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) or by visiting the NCI clinical trials Web site at www.cancer.gov/clinicaltrials.
There are requirements you must meet to take part in any clinical trial. If you do qualify for a clinical trial, it is up to you whether or not to enter (enroll in) it.
Clinical trials are one way to get state-of-the art cancer treatment. They are the only way for doctors to learn better methods to treat cancer. Still, they are not right for everyone.

Bone Marrow or Peripheral Blood Stem Cell Transplantation

The usual doses of chemotherapy drugs can cause serious side effects to quickly dividing tissues such as the bone marrow. Unfortunately, in many cases standard doses of chemotherapy aren't able to cure ALL. Even though higher doses of these drugs might be more effective, they are not given because they could severely damage the bone marrow, which is where new blood cells are formed. This could lead to life-threatening infections, bleeding, and other problems due to low blood cell counts.
A stem cell transplant (SCT) allows doctors to use higher doses of chemotherapy and, sometimes, radiation therapy. After treatment is finished, the patient receives a transplant of blood-forming stem cells to restore the bone marrow.
Blood-forming stem cells used for a transplant are obtained either from the blood (for a peripheral blood stem cell transplant, or PBSCT) or from the bone marrow (for a bone marrow transplant, or BMT). Bone marrow transplants were more common in the past, but they have largely been replaced by PBSCT.
Types of transplants
There are 2 main types of stem cell transplants: allogeneic and autologous. They differ in the source of the blood-forming stem cells.
Allogeneic stem cell transplant: In an allogeneic transplant, the stem cells come from someone else -- usually a donor whose tissue type is almost identical to the patient's. Tissue type is based on certain substances on the surface of cells in the body. These substances can cause the immune system to react against the cells. Therefore, the closer a tissue "match" is between the donor and the recipient, the better the chance the transplanted cells will "take" and begin making new blood cells.
The donor may be a brother or sister if they are a good match. Less often, a matched unrelated donor (MUD) may be found. The stem cells from an unrelated donor come from volunteers whose tissue type has been stored in a central registry and matched with the patient’s tissue type. Sometimes umbilical cord stem cells are used. These stem cells come from blood drained from the umbilical cord and placenta after a baby is born and the umbilical cord is cut.
An allogeneic stem cell transplant may be more effective than an autologous transplant because of the "graft versus leukemia" effect. When the donor immune cells are infused into the body, they may recognize any remaining leukemia cells as being foreign to them and will attack them. This effect doesn't happen with autologous stem cell transplants.
An allogeneic transplant is the preferred type of transplant for ALL when it is available, but its use is limited because of the need for a matched donor. Its use is also limited by its side effects, which are too severe for most people over 55 to 60 years old.
Autologous stem cell transplant: In an autologous transplant, a patient's own stem cells are removed from his or her bone marrow or peripheral blood. They are frozen and stored while the person gets treatment (high-dose chemotherapy and/or radiation). A process called purging may be used to try to remove any leukemia cells in the samples. The stem cells are then reinfused into the patient's blood after treatment.
Autologous transplants are sometimes used for people with ALL who are in remission after initial treatment. Some doctors feel that it is better than standard consolidation chemotherapy (see "Typical treatment of acute lymphocytic leukemia"), but not all doctors agree with this.
One problem with autologous transplants is that it is hard to separate normal stem cells from leukemia cells in the bone marrow or blood samples. Even after purging (treating the stem cells in the lab to try to kill or remove any remaining leukemia cells), there is the risk of returning some leukemia cells with the stem cell transplant.
The transplant procedure
Blood-forming stem cells from the bone marrow or peripheral blood are collected, frozen, and stored. The patient receives high-dose chemotherapy and sometimes also radiation treatment to the entire body. (Radiation shields are used to protect the lungs, heart, and kidneys from damage during radiation therapy.)
The treatments are meant to destroy any cancer cells in the body. They also kill the normal cells of the bone marrow and the immune system. After these treatments, the frozen stem cells are thawed and given as a blood transfusion. The stem cells settle into the patient's bone marrow over the next several days and start to grow and make new blood cells.
In an allogeneic SCT, the person getting the transplant may be given drugs to keep the new immune system in check. For the next few weeks the patient gets regular blood tests and supportive therapies as needed, which might include antibiotics, red blood cell or platelet transfusions, other medicines, and help with nutrition.
Usually within a couple of weeks after the stem cells have been infused, they begin making new white blood cells. This is followed by new platelet production and, several weeks later, new red blood cell production.
Patients usually stay in the hospital in protective isolation (guarding against exposure to germs) until their white blood cell count rises above 500. They may be able to leave the hospital when their white blood cell count is near 1,000. The patient is then seen in an outpatient clinic almost every day for several weeks. Because platelet counts take longer to return to a safe level, patients may get platelet transfusions as an outpatient.
Practical points
Bone marrow or peripheral blood SCT is a complex treatment. If the doctors think a patient may benefit from a transplant, it should be done at a hospital where the staff has experience with the procedure and with managing the recovery phase. Some bone marrow transplant programs may not have experience in certain types of transplants, especially transplants from unrelated donors.
SCT is very expensive (more than $100,000) and often requires a lengthy hospital stay. Because some insurance companies may view it as an experimental treatment, they may not pay for the procedure. It is important to find out what your insurer will cover before deciding on a transplant to get an idea of what you might have to pay.
Possible side effects
Side effects from SCT are generally divided into early and long-term effects.
The early complications and side effects are basically the same as those caused by any other type of high-dose chemotherapy (see the "Chemotherapy" section of this document), and are due to damage to the bone marrow and other quickly dividing tissues of the body. They can include low blood cell counts (with fatigue and an increased risk of infection and bleeding), nausea, vomiting, loss of appetite, mouth sores, and hair loss.
One of the most common and serious short-term effects is the increased risk for infection from bacteria, viruses, or fungi. Antibiotics are often given to try to prevent infections. Other side effects, like low red blood cell and platelet counts, may require blood product transfusions or other treatments.
Some complications and side effects can persist for a long time or may not occur until months or years after the transplant. These include:
  • Graft-versus-host disease (GVHD), which can occur in allogeneic (donor) transplants. This happens when the donor immune system cells attack tissues of the patient's skin, liver, and digestive tract. Symptoms can include weakness, fatigue, dry mouth, rashes, nausea, diarrhea, yellowing of the skin and eyes (jaundice), and muscle aches. In severe cases, GVHD can be life-threatening. GVHD is often described as either acute or chronic, based on how soon after the transplant it begins. Drugs that weaken the immune system are often given to try to keep GVHD under control.
  • damage to the lungs, causing shortness of breath
  • damage to the ovaries in women, causing infertility and loss of menstrual periods
  • damage to the thyroid gland that causes problems with metabolism
  • cataracts (damage to the lens of the eye that can affect vision)
  • bone damage called aseptic necrosis (where the bone dies because of poor blood supply). If damage is severe, the patient will need to have part of the bone and the joint replaced.
Graft-versus-host disease is the most serious complication of allogeneic (donor) stem cell transplants. It occurs because the immune system of the patient is taken over by that of the donor. The donor immune system then begins reacting against the patient's other tissues and organs.
The most common symptoms are severe skin rashes and severe diarrhea. The liver and lungs may also be damaged. The patient may also become tired easily and have muscle aches. Sometimes GVHD becomes chronic and disabling and, if it is severe enough, can be life-threatening. Drugs that affect the immune system may be given to try to control it.
On the positive side, graft-versus-host disease also leads to "graft-versus-leukemia" activity. Any leukemia cells remaining after the chemotherapy and radiation therapy may be killed by the immune reaction of the donor cells.
Non-myeloablative transplant (mini-transplant)
Many people over the age of 55 will not be able to tolerate a standard allogeneic transplant that uses high doses of chemotherapy. Some, however, may be able to have a non-myeloablative transplant (also known as a mini-transplant or reduced-intensity transplant), where they receive lower doses of chemotherapy and radiation that do not completely destroy the cells in their bone marrow. Then they receive the allogeneic (donor) stem cells. These cells enter the body and establish a new immune system, which sees the leukemia cells as foreign and attacks them (a "graft-versus-leukemia" effect).
Doctors have learned that if they use smaller doses of certain chemotherapy drugs and lower doses of total body radiation, an allogeneic transplant can still sometimes work with much less toxicity. In fact, a patient can receive a non-myeloablative transplant as an outpatient. The major complication is graft-versus-host disease.
Many doctors still consider this procedure to be experimental, and studies are under way to determine how useful it may be against ALL.
For more information on stem cell transplants, see our document, Bone Marrow & Peripheral Blood Stem Cell Transplants.

Radiation Therapy

Radiation therapy uses high-energy radiation to kill cancer cells. It is not usually part of the main treatment for people with ALL, but it is used in certain situations.
External beam radiation therapy, in which a machine delivers a beam of radiation to a specific part of the body, is the type of radiation used most often for ALL. Before your treatment starts, the radiation team will take careful measurements to determine the correct angles for aiming the radiation beams and the proper dose of radiation. Radiation therapy is much like getting an x-ray, but the radiation is more intense. The procedure itself is painless. Each treatment lasts only a few minutes, although the setup time -- getting you into place for treatment -- usually takes longer.
There are a few instances in which radiation therapy may be used to help treat leukemia:
  • Radiation is sometimes used to treat leukemia that has spread to the brain and spinal fluid or to the testicles.
  • Radiation is used (rarely) to help shrink a tumor if it is pressing on the trachea (windpipe) and causing breathing problems. But chemotherapy is often used instead, as it may work more quickly.
  • Radiation can also be used to reduce pain in an area of bone that is invaded by leukemia, if chemotherapy hasn't helped.
The possible side effects of radiation therapy depend on where the radiation is aimed. Sunburn-like skin changes in the treated area are possible. Radiation to the abdomen can sometimes cause nausea, vomiting, or diarrhea. For radiation that includes large parts of the body, the effects may include fatigue and an increased risk of infection.

Surgery

Surgery has a very limited role in the treatment of ALL. Because leukemia cells spread widely throughout the bone marrow and to many other organs, it is not possible to cure this type of cancer by surgery. Aside from a possible lymph node biopsy, surgery rarely has any role even in the diagnosis, since a bone marrow aspirate and biopsy can usually diagnose leukemia.
Often before chemotherapy is about to start, surgery is needed to insert a small plastic tube, called a central venous catheter or venous access device (VAD), into a large vein. The end of the tube is just under the skin or sticks out in the chest area or upper arm. The VAD is left in place during treatment to give intravenous (IV) drugs such as chemotherapy and to take blood samples. This lowers the number of needle sticks needed during treatment. It is very important to learn how to care for the device to keep it from getting infected.

Targeted Therapy

In recent years, new drugs that target specific parts of cancer cells have been developed. These targeted drugs work differently than standard chemotherapy drugs. They often have different (and less severe) side effects. Some of these drugs may be useful in certain cases of ALL.
For instance, drugs such as imatinib (Gleevec) and dasatinib (Sprycel) specifically attack cells that have the Philadelphia chromosome (a shortened chromosome 22 that results from a translocation with chromosome 9).
About 25% to 30% of adult patients with ALL have leukemia cells with this abnormal chromosome. Studies are now being done to find out if these drugs can be combined with chemotherapy to get better outcomes. Early reports have found that they may help more patients achieve a remission after treatment and may help keep the leukemia from coming back, but larger studies are needed to confirm this.
These drugs are taken daily as pills. Possible side effects include diarrhea, nausea, muscle pain, fatigue, and skin rashes. These are generally mild. A common side effect is swelling around the eyes or in the hands or feet. Some studies suggest this fluid buildup may be due to the drugs' effects on the heart. Other possible side effects include lower red blood cell and platelet counts at the start of treatment. All of these side effects get worse at higher than usual doses of the drug.

Chemotherapy

Chemotherapy is the use of anti-cancer drugs that are injected into a vein, into a muscle, under the skin, or into the cerebrospinal fluid (CSF), or are taken by mouth to destroy or control cancer cells. Except when given into the CSF, these drugs enter the bloodstream and reach all areas of the body, making this treatment useful for cancers such as leukemia that has spread throughout the body.
Doctors give chemotherapy in cycles, with each period of treatment followed by a rest period to allow the body time to recover. Because of its potential side effects, chemotherapy is sometimes not recommended for patients in poor health, but advanced age by itself is not a barrier to getting chemotherapy.
Chemotherapy for ALL uses a combination of several anti-cancer drugs given over a long period of time (usually about 2 years). The most commonly used drugs include:
  • vincristine (Oncovin)
  • daunorubicin, also known as daunomycin (Cerubidine)
  • doxorubicin (Adriamycin)
  • cytarabine, also known as cytosine arabinoside or ara-C (Cytosar)
  • L-asparaginase (Elspar), PEG-L-asparaginase (pegaspargase, Oncaspar)
  • etoposide (VePesid, others)
  • teniposide (Vumon)
  • 6-mercaptopurine (Purinethol)
  • methotrexate
  • cyclophosphamide (Cytoxan)
  • prednisone (numerous brand names)
  • dexamethasone (Decadron, others)
Possible side effects
Chemotherapy drugs work by attacking cells that are dividing quickly, which is why they work against cancer cells. But other cells in the body, such as those in the bone marrow, the lining of the mouth and intestines, and the hair follicles, also divide quickly. These cells are also likely to be affected by chemotherapy, which can lead to side effects.
The side effects of chemotherapy depend on the type and dose of drugs given and the length of time they are taken. These side effects may include:
  • hair loss
  • mouth sores
  • loss of appetite
  • nausea and vomiting
  • increased risk of infections (due to low white blood cell counts)
  • easy bruising or bleeding (due to low blood platelets)
  • fatigue (due to low red blood cells)
These side effects are usually short-term and go away once treatment is finished. There are often ways to lessen these side effects. For example, drugs can be given to help prevent or reduce nausea and vomiting. Be sure to ask your doctor or nurse about medicines to help reduce side effects, and let him or her know when you do have side effects so they can be managed effectively.
Drugs known as growth factors (G-CSF and GM-CSF, for example) are sometimes given to increase the white blood cell counts during chemotherapy to reduce the chance for infection. Because they may hasten the recovery of the white blood cell count and do not seem to cause any harm, they are often used during chemotherapy in patients with ALL.
If your white blood cell counts are very low during treatment, you can help reduce your risk of infection by carefully avoiding exposure to germs. During this time, your doctor may tell you to:
  • Wash your hands often.
  • Avoid fresh, uncooked fruits and vegetables and other foods that might carry germs.
  • Avoid fresh flowers and plants because they may carry mold.
  • Make sure other people wash their hands when they come in contact with you.
  • Avoid large crowds and people who are sick (wearing a surgical mask offers protection in these situations).
Antibiotics may be given before there are signs of infection or at the earliest sign that an infection may be developing. Drugs that help prevent viral and fungal infections may also be given.
Many of the side effects of chemotherapy are caused by low white blood cell counts. Some people find it helpful to keep track of their counts. If you are interested in this, ask your doctor or nurse about your blood cell counts and what these numbers mean.
If your platelet counts are low, you may be given drugs or platelet transfusions to help protect against bleeding. Likewise, shortness of breath and extreme fatigue caused by low red blood cell counts may be treated with drugs or with red blood cell transfusions.
Tumor lysis syndrome is another possible side effect of chemotherapy. It can be seen in patients who had large numbers of leukemia cells in the body before treatment. When chemotherapy kills these cells, they break open and release their contents into the bloodstream. This can overwhelm the kidneys, which aren't able to get rid of all of these substances at once. Excess amounts of certain minerals may also affect the heart and nervous system. This can be prevented by giving extra fluids during treatment and by giving certain drugs, such as bicarbonate, allopurinol, and rasburicase, which help the body get rid of these substances.
Some possible side effects are specific to certain drugs. For example, cytarabine (ara-C) can cause certain problems, especially when used at high doses. These can include dryness in the eyes and effects on certain parts of the brain, which can lead to coordination and balance problems.
Other organs that could be directly damaged by chemotherapy drugs include the kidneys, liver, testicles, ovaries, brain, heart, and lungs. Doctors and nurses carefully monitor treatment to reduce the risk of these side effects as much as possible.
If serious side effects occur, the chemotherapy may have to be reduced or stopped, at least for a short time. Careful monitoring and adjustment of drug doses are important because some side effects can be permanent.
One of the most serious side effects of ALL therapy is an increased risk of getting acute myelogenous leukemia (AML) at a later time. This occurs in about 5% of patients after they have received chemotherapy drugs called epipodophyllotoxins (etoposide, teniposide) or alkylating agents (cyclophosphamide, chlorambucil). Less often, people cured of leukemia may later develop non-Hodgkin lymphoma or other cancers. Of course, the risk of getting these second cancers must be balanced against the obvious benefit of treating a life-threatening disease such as leukemia with chemotherapy.

How Is Acute Lymphocytic Leukemia Treated?

This information represents the views of the doctors and nurses serving on the American Cancer Society's Cancer Information Database Editorial Board. These views are based on their interpretation of studies published in medical journals, as well as their own professional experience.
The treatment information in this document is not official policy of the Society and is not intended as medical advice to replace the expertise and judgment of your cancer care team. It is intended to help you and your family make informed decisions, together with your doctor.
Your doctor may have reasons for suggesting a treatment plan different from these general treatment options. Don't hesitate to ask him or her questions about your treatment options.
This section starts with general comments about types of treatments used for acute lymphocytic leukemia (ALL). This is followed by a discussion of the typical treatment approach for ALL in adults.
Adult acute lymphocytic leukemia (ALL) is not a single disease. It is really a group of related diseases, and patients with different subtypes of ALL vary in their outlook and response to treatment. Treatment options for each patient are based on the leukemia subtype as well as certain prognostic features (described in "How is acute lymphocytic leukemia classified?").
Several types of treatment may be used in people with ALL. The main treatment for ALL is chemotherapy. Surgery and radiation therapy may be used in special circumstances.

How Is Acute Lymphocytic Leukemia Diagnosed?

Certain signs and symptoms might suggest that a person may have acute lymphocytic leukemia (ALL), but tests are needed to confirm the diagnosis.
Signs and symptoms of acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL) can cause many different signs and symptoms. Most of these occur in all kinds of ALL, but some are more common with certain subtypes.
Generalized symptoms
Patients with ALL often have several non-specific symptoms. These can include weight loss, fever, night sweats, fatigue, and loss of appetite. Of course, these are not just symptoms of ALL and are more often caused by something other than leukemia.
Shortage of blood cells
Most signs and symptoms of ALL result from a shortage of normal blood cells, which happens when the leukemia cells crowd out the normal blood-making cells in the bone marrow. As a result, people do not have enough normal red blood cells, white blood cells, and blood platelets. These shortages show up on blood tests, but they can also cause symptoms.
  • Anemia is a shortage of red blood cells. It can cause a person to feel tired, weak, dizzy, cold, lightheaded, or short of breath.
  • A shortage of normal white blood cells (leukopenia) increases the risk of infections. A common term you may hear is neutropenia, which refers specifically to low levels of neutrophils (a type of granulocyte). Patients with ALL may have high white blood cell counts due to excess numbers of leukemia cells, but these cells do not protect against infection the way normal white blood cells do. Fevers and recurring infections are some of the most common symptoms of ALL.
  • A shortage of blood platelets (thrombocytopenia) can lead to excess bruising, bleeding, frequent or severe nosebleeds, and bleeding gums.
Swelling in the abdomen
Leukemia cells may collect in the liver and spleen, causing them to enlarge. This may be noticed as a fullness or swelling of the belly. The lower ribs usually cover these organs, but when they are enlarged the doctor can feel them.
Enlarged lymph nodes
Acute lymphocytic leukemia may spread to lymph nodes. If the affected nodes are close to the surface of the body (on the sides of the neck, in the groin, in underarm areas, above the collarbone, etc.), they may be noticed as lumps under the skin. Lymph nodes inside the chest or abdomen may also swell, but these can be detected only by imaging tests such as computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Spread to other organs
Less often, ALL may spread to other organs. If it spreads to the brain and spinal cord (central nervous system, or CNS) it can cause headaches, weakness, seizures, vomiting, trouble with balance, facial numbness, or blurred vision. ALL may also spread to the chest cavity, where it can cause fluid buildup and trouble breathing. On rare occasions it may spread to the skin, eyes, testicles, kidneys, or other organs.
Bone or joint pain
Some patients have bone pain or joint pain caused by the buildup of leukemia cells near the surface of the bone or inside the joint.
Enlarged thymus gland
The T-cell subtype of ALL often affects the thymus, which is a small gland in the middle of the chest located behind the sternum (breastbone) and in front of the trachea (windpipe). An enlarged thymus can press on the trachea, causing coughing or trouble breathing.
The superior vena cava (SVC), a large vein that carries blood from the head and arms back to the heart, passes next to the thymus. Growth of the thymus due to excess leukemia cells may press on the SVC, causing the blood to "back up" in the veins. This is known as SVC syndrome. It can cause swelling in the face, neck, arms, and upper chest (sometimes with a bluish-red color). It can also cause headaches, dizziness, and a change in consciousness if it affects the brain. The SVC syndrome can be life-threatening, and needs to be treated right away.
Medical history and physical exam
If any signs and symptoms suggest the possibility of leukemia, the doctor will want to get a thorough medical history, including how long symptoms have been present and whether or not there is any history of exposure to risk factors.
During the physical exam, the doctor will probably focus on any enlarged lymph nodes, areas of bleeding or bruising, or possible signs of infection. The eyes, mouth, and skin will be looked at carefully, and a thorough nervous system exam will be done. The abdomen will be felt for signs of an enlarged spleen or liver.
If there is reason to think the problems might be caused by abnormal numbers of blood cells (anemia, infections, bleeding or bruising, etc.), the doctor will likely test your blood counts. If the results suggest leukemia may be the cause, the doctor may refer you to a cancer doctor, who may run one or more of the tests described below.
Types of samples used to test for acute lymphocytic leukemia
If signs and symptoms and/or the results of the physical exam suggest you may have leukemia, the doctor will need to check samples of cells from your blood and bone marrow to be sure of the diagnosis. Other tissue and cell samples may also be taken to help guide treatment.
Blood samples
Blood samples for tests for ALL are generally taken from a vein in the arm.
Bone marrow samples
Bone marrow samples are obtained from a bone marrow aspiration and biopsy -- two tests that are usually done at the same time. The samples are usually taken from the back of the pelvic (hip) bone, although in some cases they may be taken from the sternum (breastbone) or other bones.
In bone marrow aspiration, you lie on a table (either on your side or on your belly). After cleaning the skin over the hip, the doctor numbs the skin and the surface of the bone with local anesthetic, which may cause a brief stinging or burning sensation. A thin, hollow needle is then inserted into the bone and a syringe is used to suck out a small amount of liquid bone marrow (about 1 teaspoon). Even with the anesthetic, most patients still have some brief pain when the marrow is removed.
A bone marrow biopsy is usually done just after the aspiration. A small piece of bone and marrow (about 1/16 inch in diameter and 1/2 inch long) is removed with a slightly larger needle that is twisted as it is pushed down into the bone. The biopsy may also briefly cause some pain. Once the biopsy is done, pressure will be applied to the site to help prevent bleeding.
These bone marrow tests are used to help diagnose leukemia. They may also be done again later to tell if the leukemia is responding to treatment.
Lumbar puncture (spinal tap)
This important test looks for leukemia cells in the cerebrospinal fluid (CSF), which is the liquid that surrounds the brain and spinal cord. A lumbar puncture can also be used to put chemotherapy drugs into the CSF to try to prevent or treat the spread of leukemia to the spinal cord and brain.
For this test, the patient may be lying on their side or sitting up. The doctor first numbs an area in the lower part of the back over the spine. A small, hollow needle is then placed between the bones of the spine to withdraw some of the fluid.
Excisional lymph node biopsy
This is often an important procedure when diagnosing lymphomas, but is only rarely needed with leukemias.
In this procedure, a surgeon cuts through the skin to remove an entire lymph node. If the node is near the skin surface, this is a simple operation that can often be done with local anesthesia, but if the node is inside the chest or abdomen, general anesthesia (where the patient is asleep) is used.
Lab tests used to diagnose and classify acute lymphocytic leukemia
One or more of the following lab tests may be done on the samples to diagnose ALL, to determine what subtype of ALL it is, and/or to help determine how advanced the disease is.
Blood cell counts and blood cell exam (peripheral blood smear)
These tests look at the numbers of the different types of blood cells and at how they look under the microscope. Changes in the numbers and the appearance of these cells often help diagnose leukemia.
Most patients with ALL have too many immature white cells in their blood, and not enough red blood cells or platelets. Many of the white blood cells will be lymphoblasts (blasts), which are immature lymphocytes not normally found in the bloodstream. These immature cells do not function like normal, mature white blood cells. Even though these findings may suggest leukemia, the disease usually is not diagnosed without looking at a sample of bone marrow cells.
Blood chemistry and coagulation tests
Blood chemistry tests measure the amounts of certain chemicals in the blood, but they are not used to diagnose leukemia. In patients already known to have ALL, these tests can help detect liver or kidney problems caused by spreading leukemia cells or the side effects of certain chemotherapy drugs. These tests also help determine if treatment is needed to correct low or high blood levels of certain minerals.
Blood coagulation tests may also be done to make sure the blood is clotting properly.
Routine microscopic exams
Any samples taken (blood, bone marrow, lymph node tissue, or CSF) are looked at under a microscope by a pathologist (a doctor specializing in lab tests) and may be reviewed by the patient's hematologist/oncologist (a doctor specializing in cancer and blood diseases).
The doctors will look at the size, shape, and other traits of the white blood cells in the samples to classify them into specific types.
A key element is whether the cells appear mature (look like normal blood cells), or immature (lacking features of normal blood cells). The most immature cells are called lymphoblasts (or "blasts" for short).
Determining what percentage of cells in the bone marrow are blasts is particularly important. A diagnosis of ALL generally requires that at least 20% to 30% of the cells in the bone marrow are blasts. Under normal circumstances, blasts are never more than 5% of bone marrow cells.
Sometimes just counting and looking at the cells does not provide a definite diagnosis, and other lab tests are needed.
Cytochemistry
In cytochemistry tests, cells are exposed to chemical stains (dyes) that react only with some types of leukemia cells. These stains cause color changes that can be seen under a microscope, which can help the doctor determine what types of cells are present. For instance, one stain can help distinguish ALL from acute myeloid leukemia (AML). The stain causes the granules of most AML cells to appear as black spots under the microscope, but it does not cause ALL cells to change colors.
Flow cytometry and immunohistochemistry
Flow cytometry is often used to look at the cells from bone marrow, lymph nodes, and blood samples. It is very helpful in determining the exact type of leukemia.
The test looks for certain substances on the surface of cells that help identify what types of cells they are. A sample of cells is treated with special antibodies (man-made versions of immune system proteins) that stick to the cells only if these substances are present on their surfaces. The cells are then passed in front of a laser beam. If the cells now have antibodies attached to them, the laser will cause them to give off light, which can be measured and analyzed by a computer. Groups of cells can be separated and counted by these methods.
In immunohistochemistry tests, cells from the blood or bone marrow samples are also treated with special antibodies. But instead of using a laser and computer, the sample is treated so that certain types of cells change color when seen under a microscope.
These tests are used for immunophenotyping -- classifying leukemia cells according to the substances (antigens) on their surfaces. Different types of lymphocytes have different antigens on their surface. These antigens also change as each cell matures. Each patient's leukemia cells should all have the same antigens because they are all derived from the same cell. Lab testing for antigens is a very sensitive way to diagnose ALL. Because cells from different subtypes of ALL have different sets of antigens, this is sometimes helpful in ALL classification, although it is not needed in most cases.
Cytogenetics
For this test, chromosomes (long strands of DNA) are looked at under a microscope to detect any changes. Normal human cells contain 23 pairs of chromosomes, each of which is a certain size and stains a certain way. In some cases of leukemia, the cells have chromosome changes that can be seen under a microscope.
For instance, 2 chromosomes may swap some of their DNA, so that part of one chromosome becomes attached to part of a different chromosome. This change, called a translocation, can usually be seen under a microscope. Recognizing these changes can help identify certain types of ALL and may be important in determining the outlook for the patient.
Most of the chromosome changes in adult ALL are translocations. The most common one is a translocation between chromosomes 9 and 22, which results in a shortened chromosome 22 (called the Philadelphia chromosome). About 25% to 30% of adults with ALL have this abnormality in their leukemia cells.
Information about this and other translocations may be useful in predicting response to treatment. For this reason, most doctors will test all patients with ALL for genetic changes in the leukemia cells.
Cytogenetic testing usually takes about 2 to 3 weeks because the leukemia cells must grow in lab dishes for a couple of weeks before their chromosomes are ready to be viewed under the microscope.
Not all chromosome changes can be seen under a microscope. Other lab tests can often help find these changes.
Fluorescent in situ hybridization (FISH)
This is similar to cytogenetic testing. It uses special fluorescent dyes that only attach to specific parts of particular chromosomes. FISH can find most chromosome changes (such as translocations) that are visible under a microscope in standard cytogenetic tests, as well as some changes too small to be seen with usual cytogenetic testing.
FISH can be used to look for specific changes in chromosomes. It can be used on regular blood or bone marrow samples. It is very accurate and can usually provide results within a couple of days, which is why this test is now used in many medical centers.
Polymerase chain reaction (PCR)
This is a very sensitive DNA test that can also find some chromosome changes too small to be seen under a microscope, even if very few leukemia cells are present in a sample.
These tests may also be used after treatment to try to find small numbers of leukemia cells that may not be visible under a microscope.
Imaging tests
Imaging tests use x-rays, sound waves, magnetic fields, or radioactive particles to produce pictures of the inside of the body. Because leukemia does not usually form visible tumors, imaging tests are of limited value. Imaging tests might be done in people with ALL, but they are done more often to look for infections or other problems, rather than for the leukemia itself. In some cases they may be done to help determine the extent of the disease, if it is thought it may have spread beyond the bone marrow and blood.
X-rays
Routine chest x-rays may be done if the doctor suspects a lung infection. They may also be done to look for enlarged lymph nodes in the chest.
Computed tomography (CT) scan
The CT scan is a type of x-ray test that produces detailed, cross-sectional images of your body. Unlike a regular x-ray, CT scans can show the detail in soft tissues (such as internal organs).
This test can help tell if any lymph nodes or organs in your body are enlarged. It isn't usually needed to diagnose ALL, but it may be done if your doctor suspects leukemia cells are growing in an organ, like your spleen.
Instead of taking one picture, as does a regular x-ray, a CT scanner takes many pictures as it rotates around you. A computer then combines these pictures into detailed images of the part of your body that is being studied.
Before the scan, you may be asked to drink a contrast solution and/or get an intravenous (IV) injection of a contrast dye that helps better outline abnormal areas in the body. You may need an IV line through which the contrast dye is injected. The IV injection of contrast dye can cause a feeling of flushing or warmth in the face or elsewhere. Some people are allergic and get hives or, rarely, more serious reactions like trouble breathing and low blood pressure. Be sure to tell the doctor if you have ever had a reaction to any contrast material used for x-rays.
CT scans take longer than regular x-rays. You need to lie still on a table while they are being done. During the test, the table moves in and out of the scanner, a ring-shaped machine that completely surrounds the table. You might feel a bit confined by the ring you have to lay in when the pictures are being taken.
Spiral CT (also known as helical CT) is now available in many medical centers. This type of CT scan uses a faster machine. The scanner part of the machine rotates around the body continuously, allowing doctors to collect the images much more quickly than standard CT. This lowers the chance of blurred images occurring as a result of body movement. It also lowers the dose of radiation received during the test. The slices it images are thinner, which yields more detailed pictures.
In some cases, a CT can be used to guide a biopsy needle precisely into a suspected abnormality, such as an abscess. For this procedure, called a CT-guided needle biopsy, you stay on the CT scanning table while a radiologist moves a biopsy needle through the skin and toward the location of the mass. CT scans are repeated until the needle is within the mass. A biopsy sample is then removed to be looked at under a microscope.
Recently, newer devices have been developed that combine the CT scan with a PET scan (PET/CT scan). For a PET scan, glucose (a form of sugar) containing a radioactive atom is injected into the blood. Because cancer cells in the body grow rapidly, they absorb large amounts of the radioactive sugar. A special camera can then create a picture of areas of radioactivity in the body. The PET/CT scan allows the doctor to compare areas of higher radioactivity on the PET scan with the more detailed appearance of that area on the CT.
Magnetic resonance imaging (MRI) scan
Like CT scans, MRI scans provide detailed images of soft tissues in the body. But MRI scans use radio waves and strong magnets instead of x-rays. The energy from the radio waves is absorbed by the body and then released in a pattern formed by the type of body tissue and by certain diseases. A computer translates the pattern into a very detailed image of parts of the body. A contrast material called gadolinium is often injected into a vein before the scan to better see details. The contrast material usually does not cause allergic reactions.
MRI scans are very helpful in looking at the brain and spinal cord.
MRI scans take longer than CT scans -- often up to an hour. You may have to lie inside a narrow tube, which is confining and can be distressing to some people. Newer, more open MRI machines may be another option. The MRI machine makes loud buzzing and clicking noises that you may find disturbing. Some places provide headphones or earplugs to help block this out.
Ultrasound
Ultrasound uses sound waves and their echoes to produce a picture of internal organs or masses. For this test, a small, microphone-like instrument called a transducer is placed on the skin (which is first lubricated with gel). The transducer emits sound waves and picks up the echoes as they bounce off the organs. The echoes are converted by a computer into an image that is displayed on a computer screen.
Ultrasound can be used to look at lymph nodes near the surface of the body or to look for enlarged organs inside your abdomen such as the kidneys, liver, and spleen.
This is an easy test to have done, and it uses no radiation. You simply lie on a table, and a technician moves the transducer over the part of your body being looked at.
Gallium scan and bone scan
These tests are not often done for ALL, but they may be useful if a patient has bone pain that might be due to either an infection or cancer in the bones.
For these tests, the doctor or nurse injects a slightly radioactive chemical into the bloodstream, which collects in areas of cancer or infection in the body. These areas can then be viewed with a special type of camera. The images from these scans are seen as "hot spots" in the body, but they don't provide much detail. If an area lights up on the scan, other imaging tests such as x-rays, CTs, or MRIs may be done to get a more detailed look at the area. If leukemia is a possibility, a biopsy of the area may be needed to confirm this.

Can Acute Lymphocytic Leukemia Be Found Early?

For many types of cancers, diagnosis at the earliest possible stage makes treatment much more effective. The American Cancer Society recommends screening tests for early diagnosis of certain cancers in people without any symptoms.
But at this time there are no special tests recommended to detect acute lymphocytic leukemia (ALL) early. The best way to find leukemia early is to report any possible signs or symptoms of leukemia (see the section, "How is acute lymphocytic leukemia diagnosed?") to the doctor right away.
Some people are known to be at increased risk of developing ALL because of an inherited disorder such as Down syndrome. Most doctors recommend that these people have careful, regular medical checkups. The development of leukemia in people with these syndromes, although greater than in the general population, is still very rare.

What Are the Key Statistics About Acute Lymphocytic Leukemia?

The American Cancer Society's estimates for leukemia in the United States for 2009 are:
  • about 44,790 new cases of leukemia (all kinds) and 21,870 deaths from leukemia (all kinds)
  • about 5,760 new cases of acute lymphocytic leukemia (ALL), of which about 1 out of 3 will be in adults
  • about 1,400 deaths from ALL, about 3 out of 4 which will be in adults
The risk for developing ALL is highest in children between 2 and 4 years of age. The risk then declines slowly until the mid-20s, and begins to rise again slowly after age 50.
The average person's lifetime risk of getting ALL is about 1/10 of 1% (about 1 in 1,000). The risk is slightly higher in men than in women, and higher in whites than in African Americans.

What Is Acute Lymphocytic Leukemia (ALL)?

Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that starts from white blood cells called lymphocytes in the bone marrow (the soft inner part of the bones, where new blood cells are made).
In most cases, the leukemia invades the blood fairly quickly. It can then spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Other types of cancer that start in these organs and then spread to the bone marrow are not leukemia.
The term "acute" means that the leukemia can progress quickly, and if not treated, would probably be fatal in a few months. "Lymphocytic" or "lymphoblastic" means it develops from cells called lymphocytes or lymphoblasts. This is different from acute myeloid leukemia (AML), which develops in other blood cell types found in the bone marrow. For more information on AML, see our document, Leukemia--Acute Myeloid.
Other types of cancer that start in lymphocytes are known as lymphomas (non-Hodgkin lymphoma or Hodgkin disease). The main difference between these types of cancers is that ALL starts in the bone marrow and may spread to other places, while lymphomas start in lymph nodes or other organs and then may spread to the bone marrow. Sometimes cancerous lymphocytes are found in both the bone marrow and lymph nodes when the cancer is first diagnosed, which can make it hard to tell if the cancer is a leukemia or a lymphoma. If more than 25% of the bone marrow is replaced by cancerous lymphocytes, the disease is usually considered to be a leukemia. The size of lymph nodes is also important. The bigger they are, the more likely the disease is a lymphoma. For more information on lymphomas, see our documents, Non-Hodgkin Lymphoma and Hodgkin Disease.
Normal bone marrow, blood, and lymphoid tissue
In order to understand the different types of leukemia, it helps to know about the blood and lymph systems.
Bone marrow
Bone marrow is the soft inner part of some bones, such as the skull, shoulder blades, ribs, pelvis, and backbones. The bone marrow is made up of a small number of blood stem cells, more mature blood-forming cells, fat cells, and supporting tissues that help cells grow.
Blood stem cells go through a series of changes to make new blood cells. During this process, the cells develop into either lymphocytes (a kind of white blood cell) or other blood-forming cells. The blood-forming cells can develop into 1 of the 3 main types of blood cell components:
  • red blood cells
  • white blood cells (other than lymphocytes)
  • platelets
Red blood cells
Red blood cells carry oxygen from the lungs to all other tissues in the body, and take carbon dioxide back to the lungs to be removed. Anemia (having too few red blood cells in the body) typically causes a person to feel tired, weak, and short of breath because the body tissues are not getting enough oxygen.
Platelets
Platelets are actually cell fragments made by a type of bone marrow cell called the megakaryocyte. Platelets are important in plugging up holes in blood vessels caused by cuts or bruises. A shortage of platelets is called thrombocytopenia. A person with thrombocytopenia may bleed and bruise easily.
White blood cells
White blood cells help the body fight infections. Lymphocytes are one type of white blood cell. The other types of white blood cells are granulocytes (neutrophils, basophils, and eosinophils) and monocytes.
Lymphocytes: These are the main cells that make up lymphoid tissue, a major part of the immune system. Lymphoid tissue is found in lymph nodes, the thymus gland, the spleen, the tonsils and adenoids, and is scattered throughout the digestive and respiratory systems and the bone marrow.
Lymphocytes develop from cells called lymphoblasts to become mature, infection-fighting cells. The 2 main types of lymphocytes are B lymphocytes (B cells) and T lymphocytes (T cells).
  • B lymphocytes: B lymphocytes protect the body from invading germs by developing (maturing) into plasma cells, which make proteins called antibodies. The antibodies attach to the germs (bacteria, viruses, and fungi), which helps other white blood cells called granulocytes to recognize and destroy them.
  • T lymphocytes: T lymphocytes can recognize cells infected by viruses and directly destroy these cells.
Granulocytes: These are white blood cells that have granules in them, which are spots that can be seen under the microscope. These granules contain enzymes and other substances that can destroy germs, such as bacteria. The 3 types of granulocytes -- neutrophils, basophils, and eosinophils -- are distinguished by the size and color of their granules. Granulocytes develop from blood-forming cells called myeloblasts to become mature, infection-fighting cells.
Monocytes: These white blood cells, which are related to granulocytes, also help protect the body against bacteria. They start in the bone marrow as blood-forming monoblasts and develop into mature monocytes. After circulating in the bloodstream for about a day, monocytes enter body tissues to become macrophages, which can destroy some germs by surrounding and digesting them. Macrophages also help lymphocytes recognize germs and start making antibodies to fight them.
Any of the blood-forming or lymphoid cells from the bone marrow can turn into a leukemia cell. Once this change takes place, the leukemia cells fail to go through their normal process of maturing. Leukemia cells may reproduce quickly, but in most cases they don't die when they should. They survive and build up in the bone marrow. Over time, these cells spill into the bloodstream and spread to other organs, where they can keep other cells in the body from functioning normally.
Types of leukemia
Not all leukemias are the same. Leukemias are divided into 4 main types. Knowing the specific type of leukemia helps doctors better predict each patient's prognosis (outlook) and select the best treatment.
Acute leukemia versus chronic leukemia
The first factor in classifying a patient's leukemia is whether most of the abnormal cells are mature (look like normal white blood cells) or immature (look more like stem cells).
Acute leukemia: In acute leukemia, the bone marrow cells cannot mature properly. Immature leukemia cells continue to reproduce and build up. Without treatment, most patients with acute leukemia would live only a few months. Some types of acute leukemia respond well to treatment, and many patients can be cured. Other types of acute leukemia have a less favorable outlook.
Chronic leukemia: In chronic leukemia, the cells can mature partly but not completely. These cells may look fairly normal, but they are not. They generally do not fight infection as well as do normal white blood cells. And they survive longer, build up, and crowd out normal cells. Chronic leukemias tend to progress over a longer period of time, and most patients can live for many years. But chronic leukemias are generally harder to cure than acute leukemias.
Myeloid leukemia versus lymphocytic leukemia
The second factor in classifying leukemia is the type of bone marrow cells that are affected.
Myeloid leukemia: Leukemias that start in early forms of myeloid cells -- white blood cells (other than lymphocytes), red blood cells, or platelet-making cells (megakaryocytes) -- are myeloid leukemias (also known as myelocytic, myelogenous, or non-lymphocytic leukemias).
Lymphocytic leukemia: If the cancer starts in early forms of lymphocytes, it is called lymphocytic leukemia (also known as lymphoid or lymphoblastic leukemia). Lymphomas are also cancers that start in lymphocytes. Lymphocytic leukemias develop from cells in the bone marrow, but lymphomas develop from cells in lymph nodes or other organs.
Leukemias can be divided into 4 main types based on whether they are acute or chronic, and whether they are myeloid or lymphocytic. The 4 main types are:
  • acute myeloid (or myelogenous) leukemia (AML)
  • chronic myeloid (or myelogenous) leukemia (CML)
  • acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • chronic lymphocytic leukemia (CLL)
ALL is the most common of the 4 major types of leukemia among children, but it is actually the least common type among adults.
The rest of this document focuses on acute lymphocytic leukemia (ALL) in adults. For information on ALL in children, please see our document, Childhood Leukemias. Chronic leukemias and acute myeloid leukemia of adults are discussed in other American Cancer Society documents.

Additional Resources

More information from your American CancerSociety
We have some related information that may also be helpful to you. These materials may be ordered from our toll-free number, 1-800-227-2345.
The following books are available from the American Cancer Society. Call us at 1-800-227-2345 to ask about costs or to place your order.
National organizations and Web sites*
In addition to the American Cancer Society, other sources of patient information and support include:
Acute lymphocytic leukemia
Leukemia & Lymphoma Society
Toll-free number: 1-800-955-4572
Web site: www.lls.org
National Cancer Institute
Toll-free number: 1-800-4-CANCER (1-800-422-6237)
Web site: www.cancer.gov
Bone marrow and peripheral blood stem cell transplants
Caitlin Raymond International Registry (for unrelated bone marrow transplants)
Toll-free number: 1-800-726-2824
Web site: www.crir.org
National Bone Marrow Transplant Link (nbmtLINK)
Toll-free number: 1-800-LINK-BMT (1-800-546-5268)
Web site: www.nbmtlink.org
National Marrow Donor Program
Toll-free number: 1-800-MARROW-2 (1-800-627-7692)
Web site: www.marrow.org
*Inclusion on this list does not imply endorsement by the American Cancer Society.
No matter who you are, we can help. Contact us anytime, day or night, for information and support. Call us at 1-800-227-2345 or visit cancer.org.